Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206


Delayed Quote. Delayed London Stock Exchange - 01/15 11:35:12 am
1577 GBX   -0.66%
01/12European ADRs Move Higher in Tuesday Trading
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
01/11European ADRs Move Sharply Lower in Monday Trading
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Emerging markets to fuel Smith & Nephew revenue growth in 2019

02/07/2019 | 04:57am EST

(Reuters) - British medical products maker Smith & Nephew forecast full-year revenue growth in line with analysts' expectations on Thursday, as it looks to grow in emerging markets and expand its product line-up.

The company has been under pressure to improve margins and find new sources of growth as it competes with bigger rivals such as Stryker Corp, Zimmer Biomet Holdings and Johnson & Johnson.

The medical technology firm, which rearranged its commercial network in November to boost sales, forecast 2019 profit margins between 22.8 percent and 23.2 percent and revenue growth between 2.5 percent and 3.5 percent, largely in line with estimates.

Smith & Nephew's established markets, including the United States from where the company gets about half of its revenue from, had returned to growth following a tough start to 2018, but have now slowed as the market saturates. Emerging markets, especially China, however, are growing.

Revenue edged up 1.3 percent to $1.29 billion (999.61 million pounds) from a year earlier, just short of average analyst forecast of $1.30 billion, according to a company-provided consensus, as growth in established markets slowed and it was hurt by a stronger dollar.

Smith & Nephew's operating profit for fiscal 2018 fell 7.6 percent to $863 million from a year earlier. Its adjusted earnings of 100.9 cents per share beat expectations of 95 cents.

The company also said that UK's decision to leave the European Union will not have any "significant impact" on its long-term ability to conduct business in the region.

(This story corrects adjusted EPS in sixth paragraph and clarifies it beat estimates, not missed).

(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham and Arun Koyyur)

© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
BYD COMPANY LIMITED -1.29% 245.8 End-of-day quote.20.96%
EURO / US DOLLAR (EUR/USD) -0.62% 1.20749 Delayed Quote.-0.52%
JOHNSON & JOHNSON -0.22% 160.3 Delayed Quote.1.86%
LETS HOLDINGS GROUP CO., LTD. 1.58% 7.72 End-of-day quote.-0.77%
LINE CORPORATION 0.00% 5350 End-of-day quote.0.00%
LOOK HOLDINGS INCORPORATED -1.07% 921 End-of-day quote.-3.76%
SMITH & NEPHEW PLC -0.66% 1577 Delayed Quote.4.44%
All news about SMITH & NEPHEW PLC
01/12European ADRs Move Higher in Tuesday Trading
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
01/11European ADRs Move Sharply Lower in Monday Trading
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
01/05SMITH & NEPHEW : Arthrex's Initial Merits Brief – Making The Case For Pate..
01/05SMITH & NEPHEW : Completes $240 Million Acquisition of Integra LifeSciences' Ext..
01/04Smith & Nephew Plc Smith+Nephew Completes Orthopaedics Acquisition
01/04SMITH & NEPHEW : +Nephew completes Extremity Orthopaedics acquisition
01/04SMITH & NEPHEW PLC : Acquisition
More news
Financials (USD)
Sales 2020 4 590 M - -
Net income 2020 377 M - -
Net Debt 2020 1 638 M - -
P/E ratio 2020 52,4x
Yield 2020 1,33%
Capitalization 18 753 M 18 762 M -
EV / Sales 2020 4,44x
EV / Sales 2021 3,75x
Nbr of Employees 17 500
Free-Float 98,7%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 23,23 $
Last Close Price 21,43 $
Spread / Highest target 25,5%
Spread / Average Target 8,43%
Spread / Lowest Target -15,7%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors